News coverage about Jazz Pharmaceuticals (NASDAQ:JAZZ) has been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Jazz Pharmaceuticals earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 45.4512510083733 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- Jazz Pharmaceuticals (JAZZ) EVP Sells $31,498.00 in Stock (americanbankingnews.com)
- BidaskClub Lowers Jazz Pharmaceuticals (JAZZ) to Sell (americanbankingnews.com)
- Jazz Pharmaceuticals (JAZZ) Upgraded by BidaskClub to Hold (americanbankingnews.com)
- Jazz Pharmaceuticals (JAZZ) Lifted to Buy at Zacks Investment Research (americanbankingnews.com)
- Jazz Pharmaceuticals (JAZZ) SVP Karen J. Wilson Sells 3,899 Shares (americanbankingnews.com)
Several equities research analysts have commented on JAZZ shares. Wells Fargo reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 25th. B. Riley reissued a “buy” rating and set a $206.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, December 20th. Piper Jaffray reaffirmed a “buy” rating and issued a $201.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, March 1st. Bank of America upped their target price on shares of Jazz Pharmaceuticals from $164.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, February 20th. Finally, Deutsche Bank set a $170.00 target price on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, January 16th. Six investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Jazz Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $180.78.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.73 by ($0.15). The company had revenue of $436.40 million during the quarter, compared to the consensus estimate of $440.91 million. Jazz Pharmaceuticals had a net margin of 30.14% and a return on equity of 22.63%. equities analysts anticipate that Jazz Pharmaceuticals will post 11.48 earnings per share for the current fiscal year.
In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $150.00, for a total transaction of $150,000.00. Following the transaction, the chief executive officer now owns 267,468 shares in the company, valued at approximately $40,120,200. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction that occurred on Friday, April 13th. The stock was sold at an average price of $157.49, for a total transaction of $31,498.00. Following the transaction, the executive vice president now owns 27,481 shares in the company, valued at approximately $4,327,982.69. The disclosure for this sale can be found here. Over the last three months, insiders sold 14,657 shares of company stock worth $2,187,294. Insiders own 4.30% of the company’s stock.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.